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Abstract
The biguanide, metformin, is the first-choice therapeutic agent for type-2 diabetes, although
the mechanisms that underpin metformin clinical efficacy remain the subject of much debate,
partly due to the considerable variation in patient response to metformin. Identification of
poor responders by genotype could avoid unnecessary treatment and provide clues to the
underlying mechanism of action. GWAS identified SNPs associated with metformin treat-
ment success at a locus containing the NPAT (nuclear protein, ataxia-telangiectasia locus)
and ATM (ataxia-telangiectasia mutated) genes. This implies that gene sequence dictates a
subsequent biological function to influence metformin action. Hence, we modified expression
of NPAT in immortalized cell lines, primary mouse hepatocytes and mouse tissues, and ana-
lysed the outcomes on metformin action using confocal microscopy, immunoblotting and
immunocytochemistry. In addition, we characterised the metabolic phenotype of npat hetero-
zygous knockout mice and established the metformin response following development of
insulin resistance. NPAT protein was localised in the nucleus at discrete loci in several cell
types, but over-expression or depletion of NPAT in immortalised cell models did not change
cellular responses to biguanides. In contrast, metformin regulation of respiratory exchange
ratio (RER) was completely lost in animals lacking one allele of npat. There was also a reduc-
tion in metformin correction of impaired glucose tolerance, however no other metabolic
abnormalities, or response to metformin, were found in the npat heterozygous mice. In sum-
mary, we provide methodological advancements for the detection of NPAT, demonstrate that
minor reductions in NPAT mRNA levels (20–40%) influence metformin regulation of RER,
and propose that the association between NPAT SNPs and metformin response observed in
GWAS, could be due to loss of metformin modification of cellular fuel usage.
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Introduction
Metformin is now the only biguanide class of drug still used in clinical practice. Interestingly
despite being the main drug prescribed for type 2 diabetes the key molecular mechanisms that
underpin metformin efficacy are still debated. There is evidence that metformin will reduce
hepatic glucose production, improve insulin sensitivity by increasing peripheral glucose
uptake and utilization, and modify the gut-brain axis [1–3]. At a molecular level, metformin
activates AMP-activated protein kinase (AMPK) and inhibits protein S6 kinase 1(S6K1) by tar-
geting a variety of proteins or protein complexes such as complex 1 of the respiratory chain,
REDD1 (regulated in DNA Damage and Development), RAG (RAS-Related GTP-binding
protein) and MID1-alpha4-protein of a PP2A complex [1, 4–8]. This wide range of potential
mechanisms may explain the considerable variation in patient response to metformin. A better
understanding of the mechanisms underlying the inter-individual difference in response could
help identify poor responders so that these patients would not undergo months of ineffective
treatment. Similarly, this knowledge may help develop much needed alternative therapies for
poor responders.
Pharmacogenomic approaches have identified genes and variants associated with the action
of metformin [9, 10]. We performed a human GWAS (genome wide association study) search-
ing for variants that influence metformin control of blood glucose in people with type 2 diabe-
tes [11]. We identified 14 SNPs within a large block of linkage disequilibrium that included 7
genes associated with metformin treatment success. Subsequent, eQTL analysis narrowed
down the genetic signal to the NPAT (nuclear protein, ataxia-telangiectasia locus; Uniprot
code- Q14207 (NPAT_HUMAN)) and ATM (ataxia-telangiectasia mutated) genes, with the
most convincing signal in NPAT. Both human NPAT and ATM genes are located on chromo-
somal 11. They share a 0.5 kb gene promoter sequence upstream of their respective transcrip-
tional start sites and are transcribed in opposite directions. Hence, these genes may be co-
ordinately regulated through common gene promoter elements, while it has been proposed
that each gene product may directly regulate the gene transcription of the other [12–14]. This
may explain why SNPs in both genes associate with metformin response. The human NPAT
gene covers 65 kb of DNA and the major transcript of the gene consists of 18 exons encoding a
protein of 1427 aa. [12, 13]. NPAT protein is involved in the acceleration of G1 phase of the
cell cycle and the activation of both histone and non-histone gene transcription [15, 16]. The
ATM gene codes for a 350 kDa protein with a structure related to PI 3-kinases [17]. It is a key
component of the DNA damage response that maintains the integrity of the genome, impacts
the response to oxidative stress, hypoxia and autophagy and modifies metabolic status [18].
Activating mutations in ATM result in ataxia telangiectasia (AT) syndrome, a disorder charac-
terised by cerebellar ataxia and oculocutaneous telangiectasia [19]. In addition to these clinical
phenotypes, AT is associated with an increased risk of diabetes and marked insulin resistance
[20, 21]. Based on our GWAS data and the physical link between ATM and NPAT genes, we
investigated whether NPAT may also modify glucose homeostasis and the response to metfor-
min. The aim was to learn more about NPAT biology and to begin to elucidate the potential
biological mechanism underlying the association of SNPs in the human NPAT gene with met-
formin control of glucose in diabetes patients.
Material and methods
Chemicals and reagents
Methanol and ethanol were from VWR International Ltd. (Poole, UK). Metformin (D150959),
phenformin (p7045), and other general chemicals were purchased from Sigma-Aldrich (Poole,
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UK). ECL Western blotting analysis system (RNP2109) was from GE Healthcare (Little Chal-
font Bucks). Dulbecco’s Modified Eagle Medium (DMEM) (41965–039, 31885–023), Dulbec-
co’s phosphate-buffered saline (DPBS) (14190), trypsin (25300–054), penicillin-streptomycin
(15140122), lipofectamine 2000, Superscript VILO Master Mix (11755–050), Taqman Univer-
sal PCR Master Mix (4324020) were from Thermo-Fisher Scientific (Perth, Scotland). HiPer-
Fect transfection reagent (301704) was from Qiagen (Manchester, UK). Microscopic glass
slides (631–0906) were from VWR International (Lutterworth, UK). Vectashield hard-set anti-
fade mounting medium with DAPI (H-1500) was from Vector Laboratories Inc. (Peterbor-
ough, UK). Details of antibodies (S1 Table), plasmids (S2 Table, oligos (S3 Table) and viruses
(S2 Table) are listed in S1–S3 Tables.
Construction of pcDNA5/RT/TO-NPAT plasmid (for conditional stable
cell line production)
NPAT cDNA was amplified by PCR using a plasmid from Origene (RC220768) as a template.
The PCR products were then extracted and purified before being ligated into the pGEM-T
Easy vector according to manufacturer instructions. The full NPAT cDNA was excised from
the pGEM-T Easy vector and cloned into the pcDNA5/RT/TO vector using the NotI restric-
tion site. Plasmid sequencing was performed to confirm successful orientation and validity of
full NPAT sequence.
Generation of stable cell lines
Stable HEK293 cells over-expressing NPAT. The HEK293 Tet-On cell line (Flp-In
T-Rex 293) purchased from Invitrogen (R780-07) was transfected with 2 μg of pcDNA5/RT/
TO-NPAT and 10 μg of pOG44 using lipofectamine 2000 (Invitrogen) according to manufac-
turer instructions. Selection of stable cell lines was initiated 2 days after transfection using
75 μg/ml hygromycin. Twelve days after transfection, single colonies were isolated and cul-
tured in 24-well plates. Cells were then expanded in 12-well and 6-well plates and finally in 25
cm2 flasks. Induced expression of NPAT in the stable cells was verified by Western blotting
using antibody sc32359.
Stable SHSY5Y cells under-expressing NPAT. SHSY-5Y cells were a kind gift from Pro-
fessor Mike Ashford, University of Dundee. MISSION shRNA lentiviral transduction particles
were used to Knock down NPAT in SHSY5Y cells. TRC1.5-pLKO.1-puro vector containing a
hairpin insert with gene-specific sequence was used for cell transduction according to manu-
facturer protocols, in addition to hexadimethrine bromide (8μg/ml), to enhance transduction
efficiency. Sequences of inserts in shRNA constructs targeting the NPAT gene are in S2 Table.
MISSION PLKO.1-Puro-CMV-TurboGFP transduction particles (SHC003V) were used to
monitor transduction efficiency. Transduced SHSY5Y cells were selected with 1 μg/ml puro-
mycin and single cells were then plated in individual wells of a 96-well plate. Cells were
expanded and the knockdown of NPAT expression was verified by Western blotting analysis.
Culture of cell lines
All cells were grown in an incubator at 37˚C and 5% CO2. HEK293, SHSY5Y and HepG2 cells
(a gift from Professor Dario Alessi, University of Dundee) were cultured in DMEM containing
4.5g/l glucose and no sodium pyruvate supplemented with 10% FCS and 1% penicillin/strepto-
mycin. H4IIe cells were grown in DMEM containing 5% FCS and 1% penicillin/streptomycin.
Primary mouse hepatocytes were isolated and maintained as described previously [22]. Stable
293 transfectants were grown in DMEM containing 4.5 g/l glucose supplemented with 10%
FCS and 1% penicillin/streptomycin, 75μg/ml hygromycin and 15 μg/ml blasticidin.
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Expression of NPAT was induced by culturing cells in fresh medium containing tetracycline at
concentrations and times as indicated in figure legends. Stable SHSY5Y transfectants were
grown in DMEM containing 4.5 g/l glucose supplemented with 10% FCS and 1% penicillin/
streptomycin.
Plasmid DNA transfection
HEK293 cells were plated in 24-well (105 cells/well) or 6-well (6x105 cells/well) plates and incu-
bated at 37˚C and 5% CO2 overnight. 4 μg (6-well) or 1 μg (24-well) of DNA was transfected
per well using lipofectamine 2000 according to the manufacturer instructions. For shRNA
transfection, HEK293 cells were plated in 6-well plates at a density of 2 x 105 cells/well and
incubated at 37˚C and 5% CO2 overnight. siRNA were transfected at final concentration of 5
nM per well using HiperFect (Qiagen) according to manufacturer protocols. Cells were incu-
bated for 24 hr prior to treatment or lysis for the preparation of protein/RNA.
Preparation of protein extract from cells and tissues
Cells were washed in ice-cold PBS and depending on the procedure to follow, collected in
Tris-Triton lysis buffer: 50 mM Tris-HCl, pH 7.4, 50 mM NaF, 1 mM Na pyrophosphate, 1
mM EDTA, 1 mM EGTA, 50 mM NaCl, 1% Triton X-100, 0.92% sucrose and protease inhibi-
tors cocktail (1183617000, Roche); IP lysis buffer: 50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1
mM EDTA, 1% Triton X-100 and protease inhibitors cocktail (1183617000, Roche); or RIPA
buffer: 50 mM Tris-HCl, pH8, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS, 2 mM PMSF, 1 mM sodium orthovanadate and protease inhibitors cocktail (1183617000,
Roche). Cell lysis was performed on ice for 20 min before being centrifuged for 20 min at
13000 rpm at 4˚C. Supernatants were collected and the pellet was resuspended in Urea lysis
buffer containing 15 mM Tris-HCl (pH 7.5), 48% urea, 8.7% glycerol, 1% SDS, 143 mM mer-
captoethanol, 0.004% bromphenol blue, and protease inhibitors cocktail (P8340, Sigma). For
the preparation of whole-cell extracts, cells were washed with PBS twice and then collected in
Urea lysis buffer. Cells were lysed for 20 min at 4˚C under constant agitation and then homog-
enized using QIAshredder spin columns according to manufacturer instructions. For the prep-
aration of tissue extracts, various tissues were manually ground in liquid nitrogen using a
mortar and pestle and the resulting tissue powder was suspended in Urea lysis buffer. Tissue
lysis was performed for 20 min at 4˚C under constant agitation and the lysates were homoge-
nized using QIAshredder spin columns according to manufacturer instructions.
Western blotting analysis
Cell or tissue lysates were heated at 95˚C for 5 min and then centrifuged at 13,000 rpm for 5
min. Equal quantities of proteins (25μg) were separated by SDS-PAGE (6% or 4–12%), trans-
ferred to PVDF membrane, incubated in blocking solution (PBS containing 0.1% Tween-20
(PBST) and 5% non-fat milk) for 1 hr at room temperature, followed by incubation overnight
at 4˚C in the primary antibodies in PBST containing 1% BSA. After washing in PBST, the
membranes were incubated in secondary antibodies in PBST for 1 hr at room temperature,
washed with PBST, and the protein signals detected using an ECL Western blotting analysis
system and Fuji Medical X-ray films. Films were scanned on a CanoScan LiDE 100 scanner
and images saved as JPG files. Densitometry of protein bands was carried out using the AIDA
densitometry software (Raytest).
PLOS ONE Metformin regulation of fuel selection is influenced by the GWAS hit; NPAT
PLOS ONE | https://doi.org/10.1371/journal.pone.0253533 July 1, 2021 4 / 20
Quantification of mRNA expression
Total RNA from cells or mouse tissues was isolated using TRI Reagent according to manufac-
turer instructions. cDNA was synthesized using SuperScript VILO MasterMix kit (Invitrogen).
Real time PCR was carried out with the 7900HT Fast Real-Time PCR System (Applied Biosys-
tems) using TaqMan 2× Universal PCR Master Mix (Applied Biosystems) and primer/ probes
sets as in S3 Table. Cycling conditions were as follows: 50˚C for 2 min, 95˚C for 10 min, fol-
lowed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. Relative levels of gene expression
were determined using the 2-ΔΔCT method with β-actin as a reference gene. Samples were ana-
lysed in triplicates.
Microscopy
Immunofluorescence. Cells were cultured on coverslips pre-treated with 50 μg/ml poly-
D-lysine (Sigma P6407). Cells were rinsed with PBS, fixed with 4% PFA for 10 min at room
temperature, washed again with PBS and then incubated in PBS-0.5% Triton X100 for 10 min.
A blocking step with 1% BSA in PBS-0.1% Tween-20 (PBST) for 30 min was carried out to
minimise non-specific antibody binding, prior to incubation overnight with an anti-NPAT
antibody (Cat. No. 611344, BD Bioscience) or an anti-ATM antibody (Cat. No. ab199726,
Abcam) (1:250 in PBST) at 4˚C. Cells were washed 3 times in PBST and incubated with a don-
key anti-mouse IgG, or donkey anti-rabbit IgG, secondary antibodies (Alexa Fluor488
(GREEN), Abcam) (1:1000 in PBST). Finally, cells were rinsed 3 times with PBST and
mounted on microscope slides with Vectorshield mounting medium with DAPI DNA stain
(H1500, Vector Laboratories). Images were acquired using a confocal microscope (Leica SP5)
with a ×40 oil immersion objective.
Immunohistochemistry. Antigen retrieval and de-paraffinisation was performed using
DAKO EnVision™ FLEX Target Retrieval solution (high pH) buffer (50x conc) (K8004) in a
DAKO PT Link for 20 min at 97˚C. Immunostaining using DAKO EnVision™ FLEX system
on a DAKO Autostainer Link48 was carried out according to manufacturer protocols. Sections
were initially washed in Flex Wash Buffer (K8006), then Flex Peroxidase-Blocking Reagent
(SM801) applied for 5 min followed by Goat serum 10%(v/v) stock avidin solution (Vector
Labs) (SP-2001) for 15 min, prior to incubation with anti-NPAT primary antibody (Bethyl
Labs A302-772A-M) at a dilution of 1:1000 in Flex Antibody Diluent (K8006) including 10%
(v/v) from stock biotin solution (Vector Labs) (SP-2001). After washing with Flex Wash Buffer
the Biotinylated anti-rabbit antibody was added for 30 min and Vectastain1 Elite ABC reagent
for a further 30 min. Next the slides were incubated with Flex DAB+ working solution
(SM803) for 2 x 5 min, Copper Sulphate solution for 5 min, then Flex Haematoxylin (SM806)
for 5 min. In between each step, sections were rinsed with Flex Wash Buffer with a final wash
in dH2O. The same protocol was used for the primary anti-ATM (Abcam EPR17059
ab199726), except the Goat serum step was not required. Sections known to stain positively
were included in each batch and negative controls were prepared by replacing the primary
antibody with DAKO antibody diluent. Slides were manually washed in tap water before being
rinsed in graded concentrations of alcohol, with a final rinse in Xylene. Glass coverslips were
applied. Images were acquired using a NIKON light microscope and a SPOT Insight QE digit
camera.
In vivo studies
Animal breeding and maintenance. All animal procedures were approved by the Univer-
sity of Dundee Ethical Review Process and were performed in accordance with UK Home
Office regulations following PPL70/8579 under the Animals (Scientific Procedures) Act 1986.
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Npat heterozygote (KO first allele reporter-tagged insertion with conditional potential) mice
on C57Bl/6Ntac background were purchased from the International Mouse Phenotyping Con-
sortium (IMPC). Both WT and heterozygote Npat mice were generated by crossing Npat tm1b
(EUCOMM)Wtsi males and females. Mice were maintained on RM1 diet (Special Diet Ser-
vices RM1 pelleted 801151) until they entered the study, and were group-housed, 4 per cage,
in the local Animal Resource Unit with ad libitum access to food and water under a 12-hour
dark/light cycle.
Study groups. High fat diet (HFD) (RM AFE 45% fat; 20% protein, 35% carbohydrate)
and HFD + 1800ppm Metformin were purchased from Special Diet Services (product codes
824053HFD and 820269 respectively). Male Npat heterozygous mice and WT littermate mice
were randomly assigned to one of 4 study groups (n = 12–14) at age 8 weeks: WT/HFD, HET/
HFD, WT HFD + Metformin (1800ppm), HET HFD + Metformin. Following a short initial
acclimatisation period of 50% HFD and 50% RM1 diet, all 4 animal groups were placed on
HFD for 23 weeks. Animals were weighed weekly at a consistent time on the same day of each
week using electronic scales.
Oral glucose tolerance tests (OGTT). OGTT were performed at weeks 6, 10 and 19 of
the study. Animals were weighed at the start of the day and fasted for 4 hr prior to recording
basal blood glucose using Bayer Contour1Glucose Meters and strips, by tail vein blood sam-
pling. Animals received an oral 50 mg glucose bolus shortly after measuring baseline glycae-
mia. Blood glucose was monitored at 0, 15, 30, 45, 60, 90 and 120 min time points. Animals
were left unrestrained in their home cages during the procedure.
EchoMRI data. Body composition data was obtained using the EchoMRI™ 4in1, in line
with the protocol provided by the manufacturer (http://www.echomri.com/Body_
Composition_4_in_1.aspx) at weeks 0, 10 and 21.
Calorimetric measurements (energy expenditure, activity and RER). Whole body
metabolism of all animals was measured in the Comprehensive Lab Animal Monitoring Sys-
tem, CLAMS/Oxymax Activity monitoring system, (Columbus Instruments International©,
2017) with software version 999 from week 23. Animals were acclimatised to single housing at
week 22. A 12:12 dark:light cycle was maintained and their access to water and respective diet
in power were provided ad libitum. Locomotor activity was measured by beam breaks in the X
and Y plane while Z recordings (rearing and jumping) were not included in the analysis.
Food intake, activity, heat and respiratory exchange ratio were recorded over the subsequent
48hr.
Tissue collection. Schedule 1 was performed on all mice following a recovery of 2 weeks
from the CLAMS system. Mice were fasted overnight then half were refed for 1 hr prior to tis-
sue harvest, with the rest sacrificed fasted. Animals were killed by cervical dislocation and con-
firmation of death was by severing the femoral artery. Tissue was snap frozen in liquid
nitrogen and stored at -80˚C. Hepatocytes were isolated from a total of 11 WT C57Bl6 animals
(male and female mix) from the breeding colony.
Statistics
Statistical analyses of the biochemical and cellular studies were performed using one-way
ANOVA with post hoc Tukey-Kramer test to accommodate for multiple comparisons or Stu-
dent’s T-test for two groups comparisons, as appropriate. Significance was set at p<0.05. All in
vivo data are presented as means ± S.E.M. A repeated measures ANOVA was performed with
genotype and drug as between subject factors. Statistical analyses were performed using Micro-
soft Excel, GraphPad Instat 3 and GraphPad Prism 5 software.
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Results
Development of an NPAT detection assay and genetically modified NPAT
cell lines
We tested commercially available NPAT antibodies for sensitivity and specificity using West-
ern blotting. Antibody sc32359 (raised against an epitope near the C-terminus of human
NPAT) recognized a protein band at ca 220 kDa in a HEK293 cell lysate (transfected with the
NPAT plasmid) (Fig 1A). This band was not detected in lysates prepared from mock trans-
fected cells or cells transfected with empty vector. We further confirmed the specificity of the
antibody by loss of the recombinant NPAT signal with a binding site blocking peptide. The dif-
ference in apparent molecular mass of the predicted (160 kDa) and the detected NPAT (220
kDa) may indicate post-translational modification. We tested the specificity of two additional
NPAT antibodies, 611344 which is specific to human NPAT a.a. 681–803, and A302-772A-M
which was raised against human NPAT a.a. 1377–1427. Antibody 611344 produced a similar
profile in lysates from cells transfected with human NPAT as antibody sc32359 (Fig 1B). In
contrast, antibody A302-772A-M recognised a range of protein bands in all the lysates, sug-
gesting some off-target interactions under these conditions (Fig 1B).
We repeated the analysis of these NPAT antibodies with alternative buffer systems. Over
expressed NPAT protein was not detected in cell lysates prepared with the IP lysis buffer or
RIPA buffer. However, strong signals were detected in the lysates prepared with Urea lysis
buffer (Fig 1C). In addition, NPAT was detected in the pellet fraction of the lysates prepared
with the Tris-Triton and IP lysis buffers, indicating that a large fraction of the NPAT protein is
insoluble (Fig 1D). Although the over-expressed NPAT was detectable in the lysates prepared
with the Urea lysis buffer, endogenous NPAT was detected more strongly after its enrichment
in the pellet of the lysates prepared with the IP lysis buffer (Fig 1D). This extraction profile
implies that NPAT is mostly associated with the chromatin and the nuclear matrix.
We next investigated the utility of the antibodies for detecting endogenous NPAT and
over-expressed NPAT in HEK293 cells by immunofluorescence. We detected NPAT as foci in
the nucleus using antibody 611344 only (Fig 1E). This localisation is consistent with the profile
of NPAT by Western blotting analysis.
Next, we generated tetracycline-inducible stable cell lines over- or under-expressing NPAT
to investigate the impact of NPAT expression level on the cellular response to metformin.
NPAT expression was 1.5-fold and 1.7-fold higher in the cells induced for 24 hr with 0.1 μg/ml
or 1 μg/ml tetracycline, respectively, compared to those without induction (Fig 1F). Based on
these results, 0.1 μg/ml of tetracycline was used in the subsequent experiments with the stable
HEK293 cells. We also generated two stable SHSY5Y cell lines carrying lentiviral vectors con-
taining shRNA constructs targeting different regions of the NPAT gene. One of the clones
(NPAT1-SH, clone 141527) shows a decrease in the expression of NPAT of 75% compared to
the control (GFP-SH) (Fig 1G).
Characterization of NPAT and ATM expression in cells and mouse tissues
There is limited information on the subcellular localisation of ATM and NPAT protein, and
the evidence of functional interaction between these gene products is only at the level of gene
expression (due to a shared gene promoter element and the binding of each protein to the
gene promoters). Therefore, we investigated whether NPAT and ATM were co-localised in
cell lines and tissues. Endogenous NPAT was detectable (green) in HEK293 (Fig 2Ai) and
HepG2 cells (Fig 2Aii) but not in H4IIe cells (Fig 2Aiii) or mouse primary hepatocytes (Fig
2Aiv). NPAT appears as discrete foci in the nucleus (DAPI-blue, 1–4 foci/nucleus).
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Endogenous ATM was undetectable by immunofluorescence, therefore we transiently trans-
fected HEK293 cells with two plasmids carrying either the wild-type ATM or the ATM with a
kinase dead mutation. Recombinant ATM is mostly localized in the nucleus, with some cyto-
plasmic staining. The patterns of the ATM staining are similar for both the wild-type (Fig
2Av) and the mutant ATM (Fig 2Avi), indicating that the kinase dead mutation does not affect
the localization of ATM protein.
Immunocytochemistry of transfected HEK293 cells also detected NPAT in the nucleus as
discrete brown foci with minimal background staining (Fig 2B, upper panels). Strong ATM
brown staining is restricted to the nucleus but in contrast to NPAT weak staining is also seen
in cytoplasm (Fig 2B, bottom panels).
We next analyzed the expression of NPAT and ATM protein in a range of mouse tissues by
Western blots. NPAT and ATM proteins are detectable in testis, spleen, kidney, pancreas and
lung tissues, with various intensities (Fig 2C and Table 1). This pattern was unexpected and
raised the possibility that NPAT and ATM may influence glucose metabolism/metformin
action through pancreatic or kidney actions rather than liver or intestine as expected. IH anal-
ysis of mouse tissues confirmed these data with strongest staining in testis (Fig 2D). As seen in
the upper panels, the immunostaining of NPAT appears in germ cells, i.e. spermatogonium
and spermatocytes. As the cells mature, the staining is lost. NPAT is again localised in the
nucleus as discrete foci. Interestingly, immunostaining of ATM is also found in the germ cells,
Fig 1. NPAT detection assay and NPAT cell line development. (A-B) HEK293 cells were transfected with NPAT plasmids for 48 hr prior to cell lysis
in Urea lysis buffer. NPAT protein was probed by Western blotting with (A) Ab sc32359 (left panel) or Ab sc32359 plus blocking peptide (right panel),
and (B) Ab sc32359 (left panel), Ab 611344 (middle panel) or Ab A30-772A-M (right panel). (C) Soluble cell lysates were prepared in Tris-Triton lysis
buffer, IP lysis buffer, RIPA lysis buffer or Urea lysis buffer, and probed with Ab sc32359. (D) Insoluble pellets from C were further lysed in Urea lysis
buffer and Western blots probed with same antibodies. (E) Immunofluorescence visualization of recombinant NPAT in HEK293 cells, detected with
Ab611344. (F) Stably transfected 293 cells were cultured for 24 hr in the presence of tetracycline (Tet) as indicated. NPAT protein was detected in
triplicate samples on Western blots with Ab sc32359 and quantified by densitometry (lower panel). (G) Cells expressing GFP-SH (control), NPAT1-SH
or NPAT2-SH (shRNA for NPAT) were lysed and NPAT protein detected on Western blots using Ab sc32359. NPAT was quantified by densitometry
(lower panel). Data are show as mean ± SEM, n = 3. One-way ANOVA with post hoc Tukey-Kramer multiple comparisons test, �p<0.05.
https://doi.org/10.1371/journal.pone.0253533.g001
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Fig 2. NPAT and ATM expression in cell lines and mouse tissues. (A) Immunofluorescence staining (green) of
endogenous NPAT in HEK293 (Ai), HepG2 (Aii), H4IIe (Aiii) cells and primary mouse hepatocytes (Aiv);
Immunofluorescence staining of ATM in HEK293 cells transfected with plasmids carrying either wild-type ATM (Av)
or ATM with a kinase dead mutation (Avi). Bar: 20 μm. Nuclei stained blue. (B) Immunohistochemical staining of
NPAT and ATM in HEK293 cells transfected with plasmids carrying either wild-type NPAT or ATM. Bar: 50 μm. (C)
Western blotting analysis of NPAT and ATM in mouse tissues. Immunohistochemical staining of NPAT and ATM in
mouse testis (D), pancreas (E), liver (F) and kidney (G); Bar: 50 μm.
https://doi.org/10.1371/journal.pone.0253533.g002
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with staining lost as the cells mature. ATM protein staining in the nucleus was much more dif-
fuse than NPAT. In the pancreas, NPAT and ATM are detected primarily in a subset of cells in
the islets of Langerhans but also in surrounding pancreatic acinar cells (Fig 2E). In liver,
immunostaining of NPAT is in a subset of hepatocytes and probably Kupffer cells, again as dis-
crete nuclear foci (Fig 2F, upper panels). ATM is undetectable in the liver (Fig 2F, bottom pan-
els). Very intense cytoplasmic staining of renal tubules and Bowman’s capsule in the kidney is
found for both NPAT and ATM (Fig 2G). This pattern requires confirming with alternative
ATM and NPAT antibodies, when available.
NPAT and ATM are not mutually regulated
The NPAT and ATM genes are physically linked, and previous work proposed that they were
functionally associated, with NPAT modifying ATM expression. However, we found that
transfection of increasing amounts of NPAT expression plasmids into HEK293 cells increased
the amount of NPAT protein (Fig 3Ai and 3Aii), without significantly altering ATM protein
levels (Fig 3Aiii). Similarly, transfection of HEK 293 cells with 1 μg of NPAT expression plas-
mid (Fig 3Bi) generated a 5-fold increase in NPAT protein (Fig 3Bii), from a 100-fold increase
in NPAT mRNA (Fig 3Biii). Again, this had no significant impact on ATM protein (Fig 3Biv)
or mRNA (Fig 3Bv). The results indicate that simple overexpression of NPAT does not affect
endogenous ATM gene expression in HEK293 cells.
For completion, we overexpressed ATM in these cells (Fig 3Ci). HEK293 cells were trans-
fected with an expression plasmid for either wild-type ATM or ATM with a kinase dead (KD)
mutation. The transfections resulted in significant increases in ATM protein (Fig 3Cii) and
mRNA (Fig 3Ciii), with no significant change in NPAT mRNA (Fig 3Civ). Hence, simple over-
expression of ATM has no effect on the expression of endogenous NPAT in these cells. Next,
we transfected HEK 293 cells with siRNA oligos, ATM5 and ATM8 for 48 hr (Fig 3Di). ATM8
resulted in a significant reduction of ATM protein compared to the control, while ATM5 had
a lesser effect (Fig 3Dii). ATM mRNA was reduced in line with the impact on ATM protein
(Fig 3Diii). In contrast, these changes in ATM expression did not alter NPAT mRNA (Fig
3Div). Hence, these factors do not appear to influence the expression of each other, at least in
this timeframe.
Table 1. Summary of detection of endogenous NPAT and ATM in mouse tissues.
Tissues NPAT ATM
IH WB IH WB
Testis +++ +++ +++ +++
Spleen NA +++ NA +++
Heart NA ND NA ND
Muscle NA ND NA ND
Kidney +++ ++ +++ ++
Pancreas ++ + ++ +
Brain NA ND NA ND
Liver + ND ND +
Lung NA ++ NA ND
Brown adipose tissue (BAT) NA ND NA ND
Write adipose tissue (WAT) NA ND NA ND
IH: immunohistochemistry; WB: Western blotting; +++: strong signal; ++: intermediate signal; +: weak signal; NA:
not applicable; ND: not detectable.
https://doi.org/10.1371/journal.pone.0253533.t001
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Changing NPAT expression does not affect cell sensitivity to biguanides
The NPAT gene lies within a genetic locus that associates with metformin response in humans
with type 2 diabetes [11]. This implies that changes in NPAT expression (or activity) moderate
metformin control of glucose homeostasis, and this could be due to changes in metformin sen-
sitivity at the level of cell signaling. We analyzed two of the best studied cellular pathways regu-
lated by metformin, namely the AMPK and S6K pathways. However, HEK 293 and SHSY5Y
cells responded relatively poorly to acute metformin challenge, even at concentrations as high
as 5 mM. In contrast, the more potent biguanide, phenformin, generated a robust acute
response in these cells. In the absence of NPAT induction, treating HEK 293 cells with phen-
formin for 6 hr (-Tet) generated a dose-dependent increase of pAMPK, and a dose-dependent
decrease of pS6 (Fig 4A and 4C). Inducing NPAT production with tetracycline (+Tet, see Fig
1F), did not alter the phenformin sensitivity of these two pathways (Fig 4B and 4D). Hence,
over-expression of NPAT in these cells didn’t change their sensitivity to acute phenformin
challenge (Fig 4A–4D). Treatment of SHSY5Y-NPAT1 (low NPAT level) and SHSY5Y-N-
PAT2 (higher NPAT level) cells (see Fig 1G for knockdown) with phenformin for 6 hr resulted
Fig 3. Changing NPAT expression in HEK293 cells had no effect on the expression of ATM and vice versa. (A) HEK293 cells were
transfected with NPAT plasmid for 24 hr as indicated. The expression of NPAT and ATM was detected by Western blotting (Ai) and quantified
by densitometry (Aii and iii). (B) HEK293 cells were transfected with 1 μg of NPAT plasmid for 24 hr. NPAT and ATM were detected by
Western blotting (Bi) and quantified by densitometry (Bii & Biv). NPAT and ATM mRNA were analysed by real-time PCR using Taqman
assay (Biii & Bv). (C) HEK293 cells were transfected with plasmids encoding ATM wild-type (ATM wt) or ATM with kinase dead mutation
(ATM kd) for 24 hr. ATM was detected on Western blots (Ci) and quantified by densitometry (Cii). ATM and NPAT mRNA were analysed by
real-time PCR using Taqman assay (Ciii & Civ). (D) HEK293 cells were transfected with ATM siRNA, ATM5 and ATM8 for 48 hr. ATM was
detected by Western blotting (Di) and quantified by densitometry (Dii). ATM and NPAT mRNA were analysed by real-time PCR using
Taqman assay (Diii & Div). Data are mean ± SEM, n = 3, and analysed by One-way ANOVA with post hoc Tukey-Kramer multiple
comparisons test (A, C and D), or unpaired Student T-test, �p<0.05.
https://doi.org/10.1371/journal.pone.0253533.g003
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Fig 4. Changing NPAT expression has no significant effect on cell signalling induced by phenformin. (A & B)
Western blotting analysis of phospho-AMPKα (P-Thr172) (pAMPKα), AMPKα, phospho-S6 (P-Ser240/P-Ser244)
(pS6), S6 and actin in cell lysates from HEK293 stably transfected with inducible NPAT (See Fig 1F). Cells were treated
with phenformin in the absence (-Tet) (A) or presence (+Tet) (B) of tetracycline (0.1 μg/ml) for 6 hr to induce NPAT
production. Western blotting data was quantified by densitometry (C & D). Western blotting analysis of pAMPKα,
AMPKα, pS6, S6 and actin (E & F), in cell lysates from NPAT1-SH and NPAT2-SH cells (NPAT knockdown-see Fig
1G). Cells were treated with phenformin for 6 hr, and immunoblots quantified by densitometry (G & H). Data are
mean ± SEM, n = 3. One-way ANOVA with post hoc Tukey-Kramer multiple comparisons test was used to calculate
the significant difference between groups. �p<0.05.
https://doi.org/10.1371/journal.pone.0253533.g004
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in a significant increase of pAMPK and a significant decrease of pS6 (Fig 4E–4H). There was
no significant difference between these two cell lines suggesting that lowering NPAT
(NPAT1-SH) does not change the sensitivity of the cells to biguanides (Fig 4E–4H).
Phenotypic analysis of npat+/- heterozygous mice
We compared the expression of NPAT and ATM in tissues from npat heterozygous mice
(npat+/-) and the wild-type littermates. Complete deletion of npat is embryonic lethal. Deletion
of one allele of npat resulted in a reduction of NPAT mRNA by 20–40% in testis, kidney and
spleen (Fig 5A). However, the mRNA of ATM was not significantly different in these tissues
from npat heterozygous mice compared to those from the wild-type littermates (Fig 5B). The
reduction of NPAT mRNA in these tissues did not induce significant changes in NPAT or
ATM protein levels, at least when measured by Western blotting (Fig 5C–5G). Of course, we
cannot rule out that deletion of an npat allele reduces NPAT protein expression in other tis-
sues, or that the Western blot technique with the available antibody is not sufficiently sensitive
to detect 10–30% changes in NPAT protein.
To investigate if deletion of one allele of npat would alter body weight, glucose metabolism
or actions of metformin in vivo, npat+/- mice and their WT littermate controls were fed with a
high-fat diet supplemented with metformin and metabolic parameters assessed. This fat feed-
ing model is commonly used to induce insulin resistance and glucose intolerance in the
C57Bl6 mice [23]. Metformin treatment significantly reduced weight gain (Fig 6A) in both
genotypes (8–12 weeks after treatment initiation), compared to no drug controls. The blunted
weight gain was accompanied by a metformin-associated reduction in percentage fat mass (Fig
6B), a concomitant increase in percentage lean mass (Fig 6C) and a lower fasting blood glucose
(Fig 6D), in both WT and npat+/- mice. Supplementation of the diet with metformin improved
glucose clearance following an oral glucose tolerance test (Fig 6E; genotype x drug; p<0.05).
However, the action of metformin on OGTT in npat+/- mice was not significant (genotype x
drug; p = 0.46), using repeated ANOVA measures. This may be due to the lower levels of glu-
cose accumulation in the blood following the OGTT (Fig 6E), however the repeated ANOVA
did not detect a significant genetic influence in the absence of metformin either. It is therefore
difficult to interpret the physiological impact of loss of one npat allele using the OGTT. To
investigate alterations in whole-body metabolism in more detail indirect calorimetry was
performed.
Most interesting was a significant genotype x drug interaction in the respiratory exchange
ratio (RER, (Fig 7A; p<0.01)), with metformin significantly reducing the RER in WT animals
during both light and dark phases (p<0.01); however, there was no metformin regulation of
the RER in npat+/- animals. Meanwhile, all animals were more active in the dark phase (Fig 7B;
effect of phase, p<0.01), with metformin-treated groups moving more than those receiving
HF diet alone (effect of drug, p<0.001). Surprisingly, the metformin-associated increase in
locomotor activity was accompanied by a genotype-independent reduction in energy expendi-
ture in both the light and dark phase (Fig 7C, effect of phase; p<0.05; effect of drug p<0.001).
In summary, the most commonly measured metabolic parameters were not affected by loss
of one allele of npat. The main exception was with metformin regulation of RER, which was
only seen in the wild-type mice. This suggests that a full complement of NPAT is required for
metformin to modify fuel utilisation in mice.
Discussion
GWAS approaches have identified genetic polymorphisms that associate with health pheno-
types in a range of human diseases [11]. They have increasingly been used to identify genetic
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variants that are associated with drug metabolism, drug efficacy and adverse effects [24].
Although huge numbers of SNP-trait associations have been identified, only a small fraction of
these associations have subsequently been investigated experimentally [24, 25]. Moving from
GWAS to biology can be very challenging, in part due to the vast number of ‘hits’ usually iden-
tified, but also as most SNPs identified are not directly associated with coding changes or
expression of known gene products. In addition, SNPs are often not conserved in the genome
of animal models routinely used in experimental biology (as human SNPs occur more fre-
quently in regions with less evolutionarily conservation [26]). This means that most experi-
mental follow ups have to focus on genes that lie ‘close’ to SNPs of interest, and delete or
overexpress those genes [27].
Our GWAS on glycaemic response to metformin in patients with type 2 diabetes identified
a strong association with variants at a locus on chromosome 11 containing 7 genes. Following
the initial discovery, further studies have established stronger links between the GWAS signal
and the response to metformin. In particular, a specific variant in NPAT gene sequence, which
results in a coding change L540F, fully explained the GWAS signal suggesting that this was the
causal variant. Meanwhile, ataxia-telangiectasia (A-T) is caused by inactivating mutations in
ATM, the gene that lies next to NPAT on chromosome 11, and is associated with metabolic
dysfunction, leading to insulin resistance, diabetes and fatty liver [20, 21, 28–30]. This associa-
tion has been described repeatedly since case reports in the 1970s, and latterly in mouse mod-
els of A-T [28, 29]. More recently, using oral glucose tolerance tests, we confirmed insulin
resistance in an A-T patient group compared to control [30].
Fig 5. Expression of NPAT and ATM in mouse tissues. (A & B) NPAT and ATM mRNA obtained by real time PCR. RNA was extracted
from testis, kidney and spleen tissues of wild-type (WT) and heterozygous (HET) NPAT+/- mice and mRNA expression levels were
calculated relative to the wild-type. (C–E) Detection of NPAT and ATM by Western blotting. Testis, kidney and spleen tissues were
collected from wild-type (WT) and heterozygous (HET) NPAT+/- mice and tissue lysates were prepared in Urea lysis buffer. Cellular
proteins (25 μg) were analysed by Western blotting using specific primary antibodies for NPAT, ATM and actin. (F & G) Quantification of
NPAT and ATM proteins by densitometry. Protein levels were calculated relative to the wild-type. Data are mean ± SEM, n = 5. Unpaired
Student t-test was used to calculate the significant difference between groups. �p<0.05.
https://doi.org/10.1371/journal.pone.0253533.g005
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Fig 6. Body composition and metabolic analysis. (A) All animals were weighed weekly throughout the study, data is
presented as weight change from study initiation. (B and C) Body composition data was obtained using the EchoMRI™
4in1. Data from week 10 of the study is presented with similar distribution at week 19. (D) Fasting blood glucose was
performed at week 20. (E) OGTT was performed at week 19 in all animals.
https://doi.org/10.1371/journal.pone.0253533.g006
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Fig 7. Energy and activity analysis. (A) Respiratory Exchange Ratio (RER), (B) Activity and (C) Energy Expenditure
were calculated at end of study (week 22) using the Comprehensive Lab Animal Monitoring System, CLAMS/Oxymax
Activity monitoring system. A 12:12 dark:light cycle was maintained with access to water and food ad libitum. Food
intake, activity, heat and respiratory exchange ratio were recorded over 48hr.
https://doi.org/10.1371/journal.pone.0253533.g007
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Therefore, there are several lines of evidence suggesting that the DNA sequence in the
ATM and NPAT gene region influences metformin response and glucose metabolism. In the
present study, we focused on the NPAT gene, however previous work had indicated the possi-
bility that the ATM gene product could regulate NPAT, and vice versa. If true, then the SNPs
in each gene that associate with metformin response may actually share a common mecha-
nism. However, our data does not support the reciprocal regulation of these gene products. In
vitro and in vivo analysis of systems with modified NPAT production did not regulate ATM
transcription, and we have data from ATM deficient mice showing no change in NPAT regula-
tion. Similarly, altering the expression of NPAT in mice had little effect on multiple aspects of
glucose metabolism and/or the pharmacological response to metformin. The interesting
exception was in control of respiratory exchange ratio (RER).
The RER is the ratio between carbon dioxide produced in metabolism and oxygen con-
sumed. It provides an indication of the fuel that is being oxidised for energy production. An
RER of 0.7 indicates fat as the predominant fuel source, while an RER of 1.0 indicates carbohy-
drate. A value between 0.7 and 1.0 shows that both are being used. We found that metformin
reduced the RER in mice on a high fat diet, indicating that it is making the animals metabolise
relatively more fat. These data may indicate that an important aspect of metformin action is to
enhance dynamic fuel switching (fuel/metabolic flexibility). Indeed, the inability to increase fat
metabolism (i.e. blunted fuel switching) is a feature of insulin resistance, and muscle from
T2D patients exhibits decreased fat oxidation capacity. This reduction of RER by metformin
has been previously reported in healthy humans [31], and in people with type 2 diabetes [32].
Indeed, reduction in RER by metformin has been postulated to contribute to the benefits of
metformin seen in people with type 2 diabetes [33, 34], despite the limited experimental evi-
dence to demonstrate a reduced metabolic flexibility in diabetes. The small reduction in whole
body NPAT production generated by deletion of one allele of npat, completely removed this
action of metformin in our fat-fed animals. Humans with a SNP in NPAT that reduces its
expression may not have access to this beneficial action of metformin. As such, we propose
that this mechanism contributes to the association of the NPAT gene sequence to metformin
response.
Additional unusual physiochemical properties are observed in individuals with ataxia- tel-
angiectasia, such as high levels of plasma alpha-fetoprotein and an increased sensitivity to ion-
ising radiation. Radiation treatment is known to alter metabolic status, mostly through
associated DNA-damage, and it is possible that the increased radiosensitivity in A-T patients is
mediated by the altered ATM and/or NPAT regulation of glucose homeostasis. Equally, some
of the impact of ATM on glucose homeostasis may be related to the role ATM has on DNA
repair mechanisms [35].
To our knowledge, this is the first gene product, identified by GWAS, that has been linked
to metformin control of metabolic flexibility. However, it will require a human study, recruit-
ing by genotype, and assessing metformin regulation of RER, to establish a clear dependence
of this metformin action on NPAT gene sequence. The data presented here provides an ethical
and scientific justification for such a study, while providing methodological developments to
allow NPAT assessment. Improved understanding of this mechanism has the potential to gen-
erate alternative strategies to modify metabolic flexibility in those patients with the metformin
resistant NPAT genotype. Clearly, despite the loss of this action of metformin we did not
detect differences in metformin regulation of fat content or the majority of glucose homeosta-
sis in these mice. This may suggest NPAT-independent actions of metformin that can over-
come this function of NPAT in the mouse, or under the treatment conditions employed in the
fat feeding model. For example, the metformin is given with the diet, and hence this is really a
‘prevention’ design, while the majority (if not all) individuals with diabetes are given
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metformin potentially years after the initiation of insulin resistance and obesity. Similarly, the
model is really one of impaired fasting glucose, or ‘pre-diabetes’ as mice are resistant to devel-
oping diabetes in response to poor diet. Hence, establishing the clinical importance of this
novel observation, placing NPAT between metformin and control of RER, will have to await
human studies in people with type 2 diabetes.
Limitations of our study
While we have tried to use distinct approaches to address the pharmacogenomic effect of altering
NPAT we have only studied outcomes in cells and in mice, where genetic manipulation is more
feasible. In addition, we have focused on a single model of obesity-related diabetes development,
and the mice do not fully develop diabetes. Finally, we have used a dose of metformin related to
that used in humans, which is lower than doses normally used in mouse studies, and as such
some of our drug responses are small, making identification of genetic influence more challeng-
ing. That said, the work provides evidence for an impact of npat on RER, and as such supports
the case to perform a trial using recruitment by genotype and RER as a primary outcome.
In summary, we have developed new tools and methodology for the study of NPAT, a gene
associated with metformin efficacy in humans. We provide evidence that ATM does not regu-
late NPAT expression and NPAT does not directly regulate ATM expression. The biological
mechanism that underpins the genetic association with metformin efficacy may include NPAT
influencing metformin control of metabolic flexibility. This data now justifies a human study
to establish the influence of NPAT genotype on metformin regulation of RER.
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